DoJ joins SEC in looking at Bristol
Executive Summary
The U.S. Attorney's Office in New Jersey "has started looking into the company's wholesaler inventory situation," Bristol reports. SEC has already opened a formal inquiry into the company's handling of inventory levels, which led Bristol to sharply cut its earnings forecasts for this year. The New Jersey investigation follows a recent meeting between SEC staff and healthcare fraud prosecutors to discuss industry accounting practices (1"The Pink Sheet" Sept. 23, p. 23)...
You may also be interested in...
Quarterly Conference Calls, In Brief
Bristol earnings restatement: Bristol-Myers Squibb expects to "reallocate" approximately $2 bil. in sales recorded during 2000 and 2001 in its upcoming 10-Q filing with the Securities & Exchange Commission. "The expected restatement is based on further review and consideration of the company's accounting for its previously disclosed wholesaler inventory situation and on recent advice from the company's auditors, PricewaterhouseCoopers LLP, based on their ongoing assessment of the company's sales practices in the U.S. pharmaceuticals business and related accounting," Bristol says. The company's accounting for wholesaler inventories is under investigation by the SEC and Department of Justice (1"The Pink Sheet" Oct. 14, In Brief)....One way to boost earnings: Bristol earnings restatement will result in increases in reported revenues and earnings in 2002 (and decreases in 2000 and 2001)...
Philadelphia Rx Fraud Investigations Have New Chief; Are SEC Cases Next?
The Philadelphia U.S. Attorney's selection of Virginia Gibson to succeed Jim Sheehan as its Civil Division chief suggests continuity in the office's prescription drug fraud and kickback investigations
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.